Evidence map›Paper›PMID 33010135›Full record

ArticleIET nanobiotechnology2020

Synthesis of surfactant-modified ZIF-8 with controllable microstructures and their drug loading and sustained release behaviour.

Xinyu Xu, Ye Liu, Zhaoming Guo, Xue-Zhi Song, Xiuyu Qi, Zideng Dai, Zhenquan Tan

Abstract read
In one paragraph

Article in IET nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xinyu XuState Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology, Panjin, Liaoning, People's Republic of China.
Ye LiuSchool of Life Science and Medicine, Dalian University of Technology, Panjin, Liaoning, People's Republic of China.
Zhaoming GuoSchool of Life Science and Medicine, Dalian University of Technology, Panjin, Liaoning, People's Republic of China.
Xue-Zhi SongState Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology, Panjin, Liaoning, People's Republic of China.
Xiuyu QiState Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology, Panjin, Liaoning, People's Republic of China.
Zideng DaiState Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology, Panjin, Liaoning, People's Republic of China.
Zhenquan TanState Key Laboratory of Fine Chemicals, School of Chemical Engineering, Dalian University of Technology, Panjin, Liaoning, People's Republic of China. tanzq@dlut.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metal-organic frameworks (MOFs) as drug carriers have many advantages than traditional drug carriers and have received extensive attention from researchers. However, how to regulate the microstructure of MOFs to improve the efficiency of drug delivery and sustained release behaviour is still a big problem for the clinical application. Herein, the authors synthesise surfactant-modified ZIF-8 nanoparticles with different microstructures by using different types of surfactants to modify ZIF-8. The surfactant-modified ZIF-8 nanoparticles have the larger specific surface area and total micropore volumes than the original ZIF-8, which enables doxorubicin (DOX) to be more effectively loaded on the drug carriers and achieve controlled drug sustained release. Excellent degradation performance of ZIF-8 nanoparticles facilitates the metabolism of drug carriers. The formulation was evaluated for cytotoxicity, cellular uptake and intracellular location in the A549 human non-small-cell lung cancer cell line. ZIF-8/DOX nano drugs exhibit higher cytotoxicity towards cells in comparison with free DOX, suggesting the potential application in nano drugs to cancer chemotherapy.

Indexed as

A549 CellsAdsorptionAntineoplastic AgentsBiocompatible MaterialsCarcinoma, Non-Small-Cell LungCell Line, TumorCell SurvivalDelayed-Action PreparationsDoxorubicinDrug CarriersDrug Delivery SystemsDrug DesignDrug LiberationEndocytosisHumansHydrogen-Ion ConcentrationAntineoplastic AgentsBiocompatible MaterialsDelayed-Action PreparationsDoxorubicinDrug CarriersMetal-Organic FrameworksSurface-Active Agents

Identifiers

PMID33010135
PMCPMC8676437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.